Fusidic acid: A bacterial elongation factor inhibitor for the oral treatment of acute and chronic staphylococcal infections

Cold Spring Harbor Perspectives in Medicine

Volumn 6, Issue 1, 2016, Pages

  Fernandes, Prabhavathi ^a  

^a Cempra Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELONGATION FACTOR; FUSIDIC ACID; RIFAMPICIN; ANTIINFECTIVE AGENT; ELONGATION FACTOR G; PROTEIN SYNTHESIS INHIBITOR;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; CROSS RESISTANCE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PH; PHARMACODYNAMICS; PREVALENCE; PROTEIN SYNTHESIS INHIBITION; STAPHYLOCOCCUS INFECTION; ACUTE DISEASE; ANTAGONISTS AND INHIBITORS; CHRONIC DISEASE; COMBINATION DRUG THERAPY; MICROBIAL SENSITIVITY TEST; ORAL DRUG ADMINISTRATION; STAPHYLOCOCCAL INFECTIONS;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FUSIDIC ACID; HUMANS; MICROBIAL SENSITIVITY TESTS; PEPTIDE ELONGATION FACTOR G; PROTEIN SYNTHESIS INHIBITORS; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS;

EID: 84953213447     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a025437     Document Type: Article

References (74)

1. Aboltins CA, Page MA, Buising KL, Jenney AW, Daffy JR, Choong PF, Stanley PA. 2007. Treatment of staphylococcal prosthetic joint infectionswith debridement, prosthesis retention and oral rifampicin and fusidic acid. Clin Microbiol Infect 13: 586-591.
2. Agrawal RK, Penczek P, Grassucci RA, Frank J. 1998. Visualization of elongation factorGon the Escherichia coli 70S ribosome: The mechanism of translocation. Proc Natl Acad Sci 95: 6134-6138.
3. Besier S, Ludwig A, Brade V, Wichelhaus TA. 2003. Molecular analysis of fusidic acid resistance in Staphylococcus aureus. Mol Microbiol 47: 463-469.
4. Besier S, Ludwig A, Brade V, Wichelhaus TA. 2005. Compensatory adaptation to the loss of biological fitness associated with acquisition of fusidic acid resistance in Staphylococcus aureus. Antimicrob Agents Chemother 49: 1426-1431.
5. Betina V. 1983. Chemical classification of antibiotics. In The chemistry and biology of antibiotics (ed. Nauta WTh, Rekker RF), pp. 154-156. Elsevier, Amsterdam.
6. Biedenbach DJ, Rhomberg PR,Mendes RE, Jones RN. 2010. Spectrum of activity, mutation rates, synergistic interactions, and the effects of pHand serum proteins for fusidic acid (CEM-102). DiagnMicrobiol Infect Dis 66: 301-307.
7. Borg A, Holm M, Shiroyama I, Hauryliuk V, Pavlov M, Sanyal S, Ehrenberg M. 2015. Fusidic acid targets elongation factor G in several stages of translocation on the bacterial ribosome. J Biol Chem 290: 3440-3454.
8. Castanheira M, Watters AA, Mendes RE, Farrell DJ, Jones RN. 2010. Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008). J Antimicrob Chemother 65: 1353-1358.
9. Chen HJ, Hung WC, Tseng SP, Tsai JC, Hsueh PR, Teng LJ. 2010a. Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother 54: 4985-4991.
10. Chen Y, Koripella RK, Sanyal S, Selmer M. 2010b. Staphylococcus aureus elongation factor G-structure and analysis of a target for fusidic acid. FEBS J 277: 3789-3803.
11. Chiang ER, Su YP, Chen TH, Chiu FY, Chen WM. 2011. Comparison of articulating and static spacers regarding infection with resistant organisms in total knee arthroplasty. Acta Orthop 82: 460-464.
12. Chung HK, Spremulli LL. 1990. Purification and characterization of elongation factor G from bovine liver mitochondria. J Biol Chem 265: 21000-21004.
13. Collignon P, Turnidge J. 1999. Fusidic acid in vitro activity. Int J Antimicrob Agents 12: S45-S58.
14. CoxG, Thompson GS, Jenkins HT, Peske F, Savelsbergh A, RodninaMV,WintermeyerW, Homans SW, Edwards TA, O'Neill AJ. 2012. Ribosome clearance by FusB-type proteins mediates resistance to the antibiotic fusidic acid. Proc Natl Acad Sci 109: 2102-2107.
15. Craft JC,Moriarty SR, Clark K, ScottD, Degenhardt TP, Still JG, Corey GR, Das A, Fernandes P. 2011. A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. Clin Infect Dis 52: S520-S526.
16. DegenhardtTP, Still JG, Clark K, Fernandes P. 2009. From mouse to man: The pharmacokinetics of CEM- 102 (fusidic acid). In 49th Interscience Conference on Antimicrobial Agents Chemotherapy, Poster A1-1930. San Francisco, CA.
17. Dobie D, Gray J. 2004. Fusidic acid resistance in Staphylococcus aureus. Arch Dis Child 89: 74-77.
18. Drancourt M, Argenson J, Roiron R, Groulier R, Raoult D. 1997. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 39: 235-240.
19. Fernandes P, Pereira D. 2011. Efforts to support the development of fusidic acid in the United States. Clin Infect Dis 52: S542-S546.
20. FerryT, Uckay I, Vaudaux P, Francois P, Schrenzel J, Harbarth S, Laurent F, Bernard L, Vandenesch F, Etienne JP, et al. 2010. Risk factors for treatment failure in orthopedic device-related methicillin-resistant Staphylococcus aureus infection. Eur J Clin Microbiol Infect Dis 29: 171- 180
21. Frank J, Agrawal RK. 2000. A ratchet-like inter-subunit reorganization of the ribosome during translocation. Nature 406: 318-322.
22. Gao YG, Selmer M, Dunham CM, Weixlbaumer A, Kelley AC, Ramakrishnan V. 2009. The structure of the ribosome with elongation factor G trapped in the posttranslocational state. Science 326: 694-699.
23. Godtfredsen WO, Vangedal S. 1966. On the metabolism of fusidic acid in man. Acta Chem Scand 20: 1599-1607.
24. Godtfredsen W, Roholt K, Tybring L. 1962. Fucidin: A new orally active antibiotic. Lancet 1: 928-931.
25. Guo X, Peisker K, Backbro K, Chen Y, Koripella RK, Mandava CS, Sanyal S, Selmer M. 2012. Structure and function of FusB: An elongation factor G-binding fusidic acid resistance protein active in ribosomal translocation and recycling. Open Biol 2: 120016.
26. HanssonS, Singh R, Gudkov AT, Liljas A, Logan DT. 2005. Structural insights into fusidic acid resistance and sensitivity in EF-G. J Mol Biol 348: 939-949.
27. Hardy DJ, Vicino D, Keedy K, Fernandes P. 2014. Susceptibility of Propionibacterium acnes to fusidic acid. In 54th Interscience Conference on Antimicrobial Agents Chemotherapy, Abstr. D-867.7. Washington, DC.
28. Howden BP, Grayson ML. 2006. Dumb and dumber- The potential waste of a useful antistaphylococcal agent: Emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis 42: 394-400.
29. JohansonU,HughesD. 1994. Fusidic acid-resistant mutants define three regions in elongation factor G of Salmonella typhimurium. Gene 143: 55-59.
30. Johanson U, Aevarsson A, Liljas A, Hughes D. 1996. The dynamic structure of EF-G studied by fusidic acid resistance and internal revertants. J Mol Biol 258: 420-432.
31. Jones RN, Li Q, Kohut B, Biedenbach DJ, Bell J, Turnidge JD. 2006. Contemporary antimicrobial activity of triple antibiotic ointment: A multiphased study of recent clinical isolates in the United States and Australia. Diagn Microbiol Infect Dis 54: 63-71.
32. Jones RN, Castanheira M, Rhomberg PR,Woosley LN, Pfaller MA. 2010a. Performance of fusidic acid (CEM-102) susceptibility testing reagents: Broth microdilution, disk diffusion, and Etest methods as applied to Staphylococcus aureus. J Clin Microbiol 48: 972-976.
33. Jones RN, Biedenbach DJ, Roblin PM, Kohlhoff SA, Hammerschlag MR. 2010b. Update on fusidic acid (CEM- 102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis. Antimicrob Agents Chemother 54: 4518- 4519.
34. Jones RN, Mendes RE, Sader HS, Castanheira M. 2011. In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) Gram-positive organisms collected in the United States. Clin Infect Dis 52: S477- S486.
35. Koripella RK, Chen Y, Peisker K, Koh CS, Selmer M, Sanyal S. 2012.Mechanism of elongation factor-G-mediated fusidic acid resistance and fitness compensation in Staphylococcus aureus. J Biol Chem 287: 30257-30267.
36. Laurberg M, Kristensen O, Martemyanov K, Gudkov AT, Nagaev I, Hughes D, Liljas A. 2000. Structure of a mutant EF-G reveals domain III and possibly the fusidic acid binding site. J Mol Biol 303: 593-603.
37. Lemaire S, Van Bambeke F, Pierard D, Appelbaum PC, Tulkens PM. 2011. Activity of fusidic acid against extracellular and intracellular Staphylococcus aureus: Influence of pH and comparison with linezolid and clindamycin. Clin Infect Dis 52: S493-S503.
38. MandellLA. 2010. Fusidic acid. In Principles and practice of infectious diseases (ed. Mandell GL, et al.), pp. 355-357. Churchill Livingstone, Philadelphia.
39. Margus T, Remm M, Tenson T. 2007. Phylogenetic distribution of translational GTPases in bacteria. BMC Genomics 8: 15.
40. MartemyanovKA, Liljas A, Yarunin AS, Gudkov AT. 2001. Mutations in the G-domain of elongation factor G from Thermus thermophilus affect both its interaction with GTP and fusidic acid. J Biol Chem 276: 28774-28778.
41. Mason BW, Howard AJ. 2004. Fusidic acid resistance in community isolates of methicillin susceptible Staphylococcus aureus and the use of topical fusidic acid: A retrospective case-control study. Int J Antimicrob Agents 23: 300-303.
42. McLaws FB, Larsen AR, Skov RL, Chopra I, O'Neill AJ. 2011. Distribution of fusidic acid resistance determinants in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 55: 1173-1176.
43. Miller K, O'Neill AJ,Wilcox MH, Ingham E, Chopra I. 2008. Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agents. Antimicrob Agents Chemother 52: 1940- 1944.
44. Nagaev I, Bjorkman J, Andersson DI, Hughes D. 2001. Biological cost and compensatory evolution in fusidic acidresistant Staphylococcus aureus. Mol Microbiol 40: 433- 439.
45. Norstrom T, Lannergard J, Hughes D. 2007. Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus. Antimicrob Agents Chemother 51: 4438-4446.
46. Okusanya OO, Tsuji BT, Bulitta JB, Forrest A, Bulik CC, Bhavnani SM, Fernandes P, Ambrose PG. 2011. Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: Implications for dose selection. Diagn Microbiol Infect Dis 70: 101-111.
47. Oldach D, Stolarski E, Murphy B, Mould D, Das A, Fernandes P. 2015. Rifampin (RIF) significantly reduces plasma concentrations of fusidic acid (FA) when used in combination for treatment of prosthetic joint infection (PJI). In 25th European Congress of Clinical Microbiology and Infectious Diseases, Poster 2352. Copenhagen, Denmark.
48. Oliva B, O'Neill AJ, Miller K, StubbingsW, Chopra I. 2004. Anti-staphylococcal activity and mode of action of clofazimine. J Antimicrob Chemother 53: 435-440.
49. O'Neill AJ, Chopra I. 2006. Molecular basis of fusB-mediated resistance to fusidic acid in Staphylococcus aureus. Mol Microbiol 59: 664-676.
50. O'Neill AJ, Cove JH, Chopra I. 2001. Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus. J Antimicrob Chemother 47: 647-650.
51. O'Neill AJ, Larsen AR, Skov R, Henriksen AS, Chopra I. 2007. Characterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus. J Clin Microbiol 45: 1505-1510.
52. Pfaller MA, Castanheira M, Sader HS, Jones RN. 2010. Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada. Int J Antimicrob Agents 35: 282-287.
53. Phee L, BB, Wareham DW. 2014. Successful treatment of multi-drug resistant Acinetobacter baumannii ventilatorassociated pneumonia with a novel colistin and fusidic acid combination therapy. In ID Week, Poster 481. Philadelphia, PA.
54. Phee LM, Betts JW, Bharathan B, Wareham DW. 2015. Colistin and fusidic acid: A novel potent synergistic combination for the treatment of multi-drug resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother 59: 4544-4550.
55. Reeves DS. 1987. The pharmacokinetics of fusidic acid. J Antimicrob Chemother 20: 467-476.
56. Sahm DF, Deane J, Pillar CM, Fernandes P. 2013. In vitro activity of CEM-102 (fusidic acid) against prevalent clones and resistant phenotypes of Staphylococcus aureus. Antimicrob Agents Chemother 57: 4535-4536.
57. Savelsbergh A, RodninaMV,WintermeyerW. 2009. Distinct functions of elongation factor G in ribosome recycling and translocation. RNA 15: 772-780.
58. Siala W, R-V H, Fernandes P, Tulkens PM, Van Bambeke F. 2015. Activity of fusidic acid (FUS) alone or in combination with daptomycin (DAP), vancomycin (VAN), or linezolid (LZD) in an in vitro model of Staphylococcus aureus biofilm. In the 25th European Congress on Clinical Microbiology and Infectious Diseases, Abstr. EV0056. Copenhagen, Denmark.
59. Spelman D. 1999. Fusidic acid in skin and soft tissue infections. Int J Antimicrob Agents 12: S59-S66.
60. StillJG, Clark K, Degenhardt TP, Scott D, Fernandes P, Gutierrez MJ. 2011. Pharmacokinetics and safety of single, multiple, and loading doses of fusidic acid in healthy subjects. Clin Infect Dis 52: S504-S512.
61. ThakerM, Spanogiannopoulos P, Wright GD. 2010. The tetracycline resistome. Cell Mol Life Sci 67: 419-431.
62. Trampuz A, Widmer AF. 2006. Infections associated with orthopedic implants. Curr Opin Infect Dis 19: 349-356.
63. Tran JH, Jacoby GA, Hooper DC. 2005. Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase. Antimicrob Agents Chemother 49: 118-125.
64. Tsuji BT, Okusanya OO, Bulitta JB, Forrest A, Bhavnani SM, Fernandez PB, Ambrose PG. 2011. Application of pharmacokinetic- pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: Raising Lazarus from the dead. Clin Infect Dis 52: S513-S519.
65. TurnidgeJ. 1999. Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 12: S23-S34.
66. VaillantL, Machet L, Taburet AM, Sorensen H, Lorette G. 1992. Levels of fusidic acid in skin blister fluid and serum after repeated administration of two dosages (250 and 500 mg). Br J Dermatol 126: 591-595.
67. Vaillant L, Le Guellec C, Jehl F, Barruet R, Sorensen H, Roiron R, Autret-Leca E, Lorette G. 2000. Comparative diffusion of fusidic acid, oxacillin, and pristinamycin in dermal interstitial fluid after repeated oral administration. Ann Dermatol Venereol 127: 33-39.
68. Verbist L. 1990. The antimicrobial activity of fusidic acid. J Antimicrob Chemother 25: 1-5.
69. von Daehne W, Godtfredsen WO, Rasmussen PR. 1979. Structure-activity relationships in fusidic acid-type antibiotics. Adv Appl Microbiol 25: 95-146.
70. Williamson DA, Monecke S, Heffernan H, Ritchie SR, Roberts SA, Upton A, Thomas MG, Fraser JD. 2014. High usage of topical fusidic acid and rapid clonal expansion of fusidic acid-resistant Staphylococcus aureus: A cautionary tale. Clin Infect Dis 59: 1451-1454.
71. Wilson DN. 2014. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. Nat Rev Microbiol 12: 35-48.
72. Wolfe CR. 2011. Case report: Treatment of chronic osteomyelitis. ClinInfect Dis 52: S538-S541.
73. WulltM, Odenholt I. 2004. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficileassociated diarrhea. J Antimicrob Chemother 54: 211-216.
74. Zimmerli W, Trampuz A, Ochsner PE. 2004. Prostheticjoint infections. N Engl J Med 351: 1645-1654.